GLAUKOS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Stifel reiterated a Buy rating and $190 price target for Glaukos (GKOS), citing strong iDose growth and positive payer mix results. GKOS shares have risen 94% over the past year. The company reported Q2 2026 revenue of $185.6M, up 49.5% YoY. Analysts have raised price targets, with Truist setting the highest at $215.
Glaukos reported its Phase 4 trial met the primary endpoint, showing iDose TR with cataract surgery reduced mean diurnal IOP by 11.1 mmHg at 3 months, compared to 7.4 mmHg for surgery alone, with a 3.6 mmHg incremental reduction. The safety profile was consistent through 3 months, according to the company.
Glaukos Corp. (GKOS) shares fell 11% after announcing an exclusive licensing deal with RevOpsis Therapeutics for RO-104, a biologic for retinal diseases. The stock is trading at $153.65, down from $172.18.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GKOS (GLAUKOS Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GKOS coverage spans financial news, market movers and earnings.
In the last 30 days, GKOS insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($500K). The most active reporter was Navratil Tomas, CHIEF DEVELOPMENT OFFICER, with 7 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade with a higher price target suggests upside potential.
Positive Phase 4 data may boost investor confidence and drive the stock higher.
Deal-driven sentiment is negative near term, likely reflecting dilution of economics or execution risk around RO-104 commercialization.
Positive long‑term trial data supports commercial rollout of Epioxa, likely boosting investor sentiment.
The new earnings‑date disclosure and high‑profile marketing push are likely to sustain buying pressure.
AlphAI scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel reiterated a Buy rating and $190 price target for Glaukos (GKOS), citing strong iDose growth and positive payer mix results. GKOS shares have risen 94% over the past year. The company reported Q2 2026 revenue of $185.6M, up 49.5% YoY. Analysts have raised price targets, with Truist setting the highest at $215.
2 min readGlaukos reported its Phase 4 trial met the primary endpoint, showing iDose TR with cataract surgery reduced mean diurnal IOP by 11.1 mmHg at 3 months, compared to 7.4 mmHg for surgery alone, with a 3.6 mmHg incremental reduction. The safety profile was consistent through 3 months, according to the company.
1 min readGlaukos Corp. (GKOS) shares fell 11% after announcing an exclusive licensing deal with RevOpsis Therapeutics for RO-104, a biologic for retinal diseases. The stock is trading at $153.65, down from $172.18.
2 min readGlaukos (GKOS) reported 3-year Phase 3 extension data for Epioxa, showing sustained 1.9D Kmax improvement in keratoconus with no serious adverse events. The results support ongoing commercialization.
1 min readGlaukos Corp (GKOS) stock rose 5.3% to $170.21 after announcing Q3 2026 earnings release on October 28 and a keratoconus awareness campaign with NBA Champion Stephen Curry. Analysts have a consensus price target of $180.54. GKOS reported record Q2 sales up 50% YoY and raised 2026 revenue guidance to $680M-$700M.
2 min readGlaukos (GKOS) shares rose 89.3% over the past year, driven by strong adoption of iDose TR and Epioxa. Q2 2026 revenue was $185.61M, up from $124.12M a year earlier, with management raising 2026 sales guidance. The company reported a loss of $18.38M and a declining net margin of 9.9%. Analysts remain divided on its future, with optimistic and cautious Fair Value estimates at $123 and $74.28, respectively.
2 min readStifel maintained a Buy rating and $190 price target for Glaukos (NYSE:GKOS) after a survey showed strong demand for its Epioxa product, with Q3 2026 procedures increasing fourfold. The firm estimates Q3 Epioxa sales between $30M and $44M, and Q4 sales between $65M and $70M. Glaukos reported Q2 2026 revenue of $185.6M, up 49.5% YoY, exceeding expectations and prompting multiple analysts to raise price targets.
2 min readArgus lowered its target price for Glaukos Corporation (GKOS) to $168.00. The company focuses on ophthalmic treatments for glaucoma, corneal disorders, and retinal diseases.
1 min readGlaukos (GKOS) officer Tomas Navratil plans to sell 1,457 shares of common stock, tied to restricted stock vesting events in March 2025. The sale is part of a Rule 144 notice, with prior sales also reported. The shares are part of Navratil's compensation.
1 min readGlaukos Corp (GKOS) shares fell 5.2% to $170.38, within a 52-week range of $73.16 to $191.62. The stock is up 94.7% year-to-date but has declined 5.5% in the past week and 6.1% in the past month. GuruFocus values GKOS at $151.61, suggesting it is 12.4% overvalued. The company has a GF Score of 77/100, indicating above-average performance. Insiders sold $67.6M in shares over the past year with no buying.
2 min read
